Safety, tolerability, and immunogenicity of a DNA-based vaccine (INO-4700) against Middle East respiratory syndrome coronavirus: phase 2a study in healthy volunteers.
Saved in:
| Title: | Safety, tolerability, and immunogenicity of a DNA-based vaccine (INO-4700) against Middle East respiratory syndrome coronavirus: phase 2a study in healthy volunteers. |
|---|---|
| Authors: | Agnes JT; Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, United States., Marcus SA; Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, United States., Al-Ghraibeh SS; Department of Internal Medicine, Faculty of Medicine, Yarmouk University, Irbid, Jordan., Al-Sweedan SA; Department of Pediatric Hematology/Oncology/BMT, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science & Technology, Ar Ramtha, Irbid, Jordan., Kosgei J; Kenya Medical Research Institute/Walter Reed Project Clinical Research Center, Kericho Clinical Research Site, Kericho, Kenya., Ogutu B; Kenya Medical Research Institute (KEMRI), Nairobi, Kenya., Yang S; Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, United States., Walker KA; Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, United States., Orizu B; Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, United States., Broderick KE; Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, United States., Boyer J; Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, United States., Ramos S; Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, United States., Morrow MP; Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, United States., Kraynyak K; Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, United States., Sylvester AJ; Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, United States., Gillespie E; Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, United States., Liebowitz D; Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, United States., Humeau LM; Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2025 Nov 14; Vol. 16, pp. 1662923. Date of Electronic Publication: 2025 Nov 14 (Print Publication: 2025). |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2025.1662923 |
